Synergistic Effect of Curcumin and Tamoxifen Loaded in PH-responsive Gemini Surfactant Nanoparticles on Breast Cancer Cells

Overview

Journal BMC Complement Med Ther

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2024 Sep 20

PMID 39304876

Authors

Zeinab Fotouhi Ashin

Sanam Sadeghi-Mohammadi

Zahra Vaezi

Farhood Najafi

Shaghayegh AdibAmini

Majid Sadeghizadeh

Hossein Naderi-Manesh

Affiliations

Soon will be listed here.

Abstract

Background: Drug combination therapy is preferred over monotherapy in clinical research to improve therapeutic effects. Developing a new nanodelivery system for cancer drugs can reduce side effects and provide several advantages, including matched pharmacokinetics and potential synergistic activity. This study aimed to examine and determine the efficiency of the gemini surfactants (GSs) as a pH-sensitive polymeric carrier and cell-penetrating agent in cancer cells to achieve dual drug delivery and synergistic effects of curcumin (Cur) combined with tamoxifen citrate (TMX) in the treatment of MCF-7 and MDA-MB-231 human BC cell lines.

Methods: The synthesized NPs were self-assembled using a modified nanoprecipitation method. The functional groups and crystalline form of the nanoformulation were examined by Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), differential scanning calorimetry (DSC), and dynamic light scattering (DLS) used to assess zeta potential and particle size, and the morphological analysis determined by transmission electron microscopy (TEM). The anticancer effect was evaluated through an in vitro cytotoxicity MTT assay, flow cytometry analysis, and apoptosis analysis performed for mechanism investigation.

Results: The tailored NPs were developed with a size of 252.3 ± 24.6 nm and zeta potential of 18.2 ± 4.4 mV capable of crossing the membrane of cancer cells. The drug loading and release efficacy assessment showed that the loading of TMX and Cur were 93.84% ± 1.95% and 90.18% ± 0.56%, respectively. In addition, the drug release was more controlled and slower than the free state. Polymeric nanocarriers improved controlled drug release 72.19 ± 2.72% of Tmx and 55.50 ± 2.86% of Cur were released from the Tmx-Cur-Gs NPs after 72 h at pH = 5.5. This confirms the positive effect of polymeric nanocarriers on the controlled drug release mechanism. moreover, the toxicity test showed that combination-drug delivery was much more greater than single-drug delivery in MCF-7 and MDA-MB-231 cell lines. Cellular imaging showed excellent internalization of TMX-Cur-GS NPs in both MCF-7 and MDA-MB-231 cells and synergistic anticancer effects, with combination indices of 0.561 and 0.353, respectively.

Conclusion: The combined drug delivery system had a greater toxic effect on cell lines than single-drug delivery. The synergistic effect of TMX and Cur with decreasing inhibitory concentrations could be a more promising system for BC-targeted therapy using GS NPs.

Citing Articles

Current Evidence on the Impact of Diet, Food, and Supplement Intake on Breast Cancer Health Outcomes in Patients Undergoing Endocrine Therapy.

Zuza Prastalo M, Pokimica B, Arsic A, Ilich J, Vucic V Nutrients. 2025; 17(3).

PMID: 39940314 PMC: 11820974. DOI: 10.3390/nu17030456.

References

Jose A, Ninave K, Karnam S, Venuganti V . Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment. J Liposome Res. 2018; 29(2):153-162. DOI: 10.1080/08982104.2018.1502315. View

Ni W, Li Z, Liu Z, Ji Y, Wu L, Sun S . Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma. J Pharm Sci. 2018; 108(3):1284-1295. DOI: 10.1016/j.xphs.2018.10.042. View

Cao J, Zhang H, Wang Y, Yang J, Jiang F . Investigation on the interaction behavior between curcumin and PAMAM dendrimer by spectral and docking studies. Spectrochim Acta A Mol Biomol Spectrosc. 2013; 108:251-5. DOI: 10.1016/j.saa.2013.02.003. View

Ali S, Rasool M, Chaoudhry H, Pushparaj P, Jha P, Hafiz A . Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation. 2017; 12(3):135-139. PMC: 5267957. DOI: 10.6026/97320630012135. View

Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H . Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules. 2013; 18(1):701-20. PMC: 6269686. DOI: 10.3390/molecules18010701. View

Maji R, Dey N, Satapathy B, Mukherjee B, Mondal S . Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy. Int J Nanomedicine. 2014; 9:3107-18. PMC: 4077606. DOI: 10.2147/IJN.S63535. View

Sinha R, Kim G, Nie S, Shin D . Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006; 5(8):1909-17. DOI: 10.1158/1535-7163.MCT-06-0141. View

Cho Y, Lee W, Choi J . Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin. Pharmazie. 2012; 67(2):124-30. View

Martinez-Edo G, Fornaguera C, Borros S, Sanchez-Garcia D . Glycyrrhetinic Acid-Functionalized Mesoporous Silica Nanoparticles for the Co-Delivery of DOX/CPT-PEG for Targeting HepG2 Cells. Pharmaceutics. 2020; 12(11). PMC: 7694026. DOI: 10.3390/pharmaceutics12111048. View

10.

Baghi N, Bakhshinejad B, Keshavarz R, Babashah S, Sadeghizadeh M . Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer effects on breast cancer cells. Gene. 2018; 670:55-62. DOI: 10.1016/j.gene.2018.05.025. View

11.

Khan M, Madni A, Tahir N, Parveen F, Khan S, Jan N . Co-Delivery of Curcumin and Cisplatin to Enhance Cytotoxicity of Cisplatin Using Lipid-Chitosan Hybrid Nanoparticles. Int J Nanomedicine. 2020; 15:2207-2217. PMC: 7125308. DOI: 10.2147/IJN.S247893. View

12.

Gou M, Men K, Shi H, Xiang M, Zhang J, Song J . Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale. 2011; 3(4):1558-67. DOI: 10.1039/c0nr00758g. View

13.

Frohlich E . The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012; 7:5577-91. PMC: 3493258. DOI: 10.2147/IJN.S36111. View

14.

Zhang X, Huang J, Yu C, Xiang L, Li L, Shi D . Quercetin Enhanced Paclitaxel Therapeutic Effects Towards PC-3 Prostate Cancer Through ER Stress Induction and ROS Production. Onco Targets Ther. 2020; 13:513-523. PMC: 6970612. DOI: 10.2147/OTT.S228453. View

15.

Peyvand P, Vaezi Z, Sedghi M, Dalir N, Mamani L, Naderi-Manesh H . Imidazolium-based ionic liquid functionalized mesoporous silica nanoparticles as a promising nano-carrier: response surface strategy to investigate and optimize loading and release process for Lapatinib delivery. Pharm Dev Technol. 2020; 25(9):1150-1161. DOI: 10.1080/10837450.2020.1803909. View

16.

Zhai B, Zhang N, Han X, Li Q, Zhang M, Chen X . Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review. Biomed Pharmacother. 2019; 114:108812. DOI: 10.1016/j.biopha.2019.108812. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

van Riel Neto F, Foschini M, Tozoni J, Piovesan E, Cristovan F, Marletta A . Optical spectroscopy study of the interaction between curcumin and acrylic polymers. Spectrochim Acta A Mol Biomol Spectrosc. 2021; 260:119954. DOI: 10.1016/j.saa.2021.119954. View

19.

Hajigholami S, Malekshahi Z, Bodaghabadi N, Najafi F, Shirzad H, Sadeghizadeh M . Nano Packaged Tamoxifen and Curcumin; Effective Formulation against Sensitive and Resistant MCF-7 Cells. Iran J Pharm Res. 2018; 17(1):1-10. PMC: 5937073. View

20.

Qi C, Wang D, Gong X, Zhou Q, Yue X, Li C . Co-Delivery of Curcumin and Capsaicin by Dual-Targeting Liposomes for Inhibition of aHSC-Induced Drug Resistance and Metastasis. ACS Appl Mater Interfaces. 2021; 13(14):16019-16035. DOI: 10.1021/acsami.0c23137. View